About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The main characteristic of our group is its multidisciplinary nature, as it is comprised of neuroradiologists, technologists, and a physicist, engineer, and biochemist.
The main objectives of our projects are to gain knowledge about the pathophysiologic mechanisms implicated in several neurological diseases and to evaluate new biomarkers and therapies through the use of qualitative and quantitative magnetic resonance (MR) and computed tomography (CT) techniques, and by applying artificial intelligence tools to create prognostic models. Our focus is on the study of diseases such as multiple sclerosis, epilepsy, neuro-oncology, and stroke.
In addition, because of the experience we have acquired along the years in performing MR studies, we act as a platform for designing MR-based projects, processing images, and conducting quantitative data analysis.
The objective of this research line is to evaluate the value of MRI in the diagnosis of multiple sclerosis and as a marker of progression and treatment response to disease modifying treatments.
IP: Alex Rovira Cañellas, Cristina Auger Acosta
The objective of this research line is to evaluate the value of MRI in the diagnosis and follow-up of primary tumours of central nervous system, with special interest on the impact of radiological features in predicting their genomics characteristics (radiogenomics), through multicentre studies.
IP: Cristina Auger Acosta
The objective of this research line is to evaluate the value of MRI in the diagnosis and follow-up of primary tumours of the head and neck, with special interest on the impact of radiological features in their prognosis.
IP: -
This research line aims to develop new biomarkers that capture brain function and can be implemented in the clinical routine.
IP: Deborah Pareto Onghena
IP: Jaume Sastre Garriga Collaborators: Cristina Auger Acosta, Carme Santoyo Medina, Manel Alberich Jordà, M Jesus Arevalo Navines, Xavier Montalban Gairín, Lucía Gutiérrez Ruiz, Neus Mongay Ochoa Funding agency: Instituto de Salud Carlos III Funding: 157300 Reference: PI22/00750 Duration: 01/01/2023 - 31/12/2025
IP: Deborah Pareto Onghena Collaborators: Ingrid Galán Cartaña, Herena Eixarch Ahufinger, M Jesus Arevalo Navines, Neus Mongay Ochoa, Giorgio Colangelo Funding agency: Instituto de Salud Carlos III Funding: 87120 Reference: PI22/01709 Duration: 01/01/2023 - 31/12/2025
IP: Angela Vidal Jordana Collaborators: Dulce María Moncho Rodríguez, Alex Rovira Cañellas, Manel Alberich Jordà, Neus Mongay Ochoa, Joaquin Castillo Justribo, Sergio Cabello Funding agency: Instituto de Salud Carlos III Funding: 48400 Reference: PI22/01589 Duration: 01/01/2023 - 31/12/2025
IP: Alvaro Cobo Calvo Collaborators: Rosalia Horno Ocaña, Cristina Auger Acosta, Luciana Midaglia Fernandez, Breogan Rodriguez Acevedo, Mireia Castillo Juarez Funding agency: Instituto de Salud Carlos III Funding: 134915 Reference: PI20/00800 Duration: 01/01/2021 - 30/06/2025
Dr. Xavier Montalban, Dr. Álex Rovira, Dr. Mar Tintoré and Dr. Jaume Sastre Garriga have been recognised in the listing.
Her nomination means that she will represent UPF in the national competition held annually.
The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.
Magnetic Resonance image analysis
